2. Metabolic Enzyme/Protease MAPK/ERK Pathway GPCR/G Protein Apoptosis Autophagy
  3. Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3
  4. Manumycin A

Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion.

For research use only. We do not sell to patients.

Manumycin A Chemical Structure

Manumycin A Chemical Structure

CAS No. : 52665-74-4

Size Price Stock Quantity
1 mg USD 230 In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Manumycin A Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

View All Phospholipase Isoform Specific Products:

View All Isoforms
Phospholipase A PLD Phospholipase C

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion[1][3][4].
IC50 & Target

TrxR-1[1], Ras[4]
In Vitro

Manumycin A (0.25-5 μM, 24 h) downregulates the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, thus possessing potential anti-inflammatory properties[1].
Manumycin A (0-25 μM, 72 h) can enhance its inhibitory effect on lung cancer cells after inhibiting HSF1 mediated heat shock response (HSR)[2].
Manumycin A (5 μM, 72 h) inhibits the growth of triple negative breast cancer cells through LC3 mediated cytoplasmic vacuolation death[3].
Manumycin A (250 nM, 48 h) inhibits exosome biogenesis and secretion by targeting Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Manumycin A Related Antibodies

Real Time qPCR[1].

Cell Line: Human monocytic leukemia cells THP-1
Concentration: 0.25-5 μM
Incubation Time: 24 h
Result: Inhibited the production and release of IL-1 β, IL-6, and IL-8.

Cell Viability Assay[2].

Cell Line: Lung cancer cell lines NCI-H1299, NCI-H23, A549
Concentration: 0-25 μM
Incubation Time: 72 h
Result: Enhances growth inhibition of NSCLC cells after inhibiting HSPA1 expression.

Cell Viability Assay[3].

Cell Line: Triple-negative breast cancer (TNBC) cells (MDA-MB-231, HCC1937, BT-20)
Concentration: 5 μM
Incubation Time: 72 h
Result: Inhibited the cell viability of different TNBC cell lines.

Western Blot Analysis[4].

Cell Line: C4-2B cell
Concentration: 250 nM
Incubation Time: 48 h
Result: Reduced protein levels of extracellular vesicle biogenic markers Alix, Hrs, and Rab27a.
In Vivo

Manumycin A (5 mg/kg; once every two days; 2 weeks; i.p.) has anti-tumor effect in triple negative breast cancer mice[3].
Manumycin A (3 μg; once; i.m.) can correct abnormal splicing of Clcn1 in type 1 myotonic dystrophy (DM1) mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude mice with breast cancer transplanted with MDAMB-231 cells[3].
Dosage: 5 mg/kg
Administration: Intraperitoneal injection (i.p.); Once every two days; 2 weeks
Result: Inhibited tumor growth and increased levels of ER stress markers such as Bip, CHOP, LC3, and p62 proteins, as well as higher molecular weight ubiquitinated proteins.
Animal Model: HSALR transgenic mice[5].
Dosage: 3 μg
Administration: Intramuscular injection (i.m.); once
Result: Reduced the content of Clcn1 exon 7A introns.
Molecular Weight

550.64

Formula

C31H38N2O7
CAS No.
Appearance

Solid

Color

Yellow to orange

SMILES

CCCC[C@@H](C)/C=C(C)/C=C(C)/C(NC1=C[C@](/C=C/C=C/C=C/C(NC2=C(O)CCC2=O)=O)(O)[C@]3([H])O[C@]3([H])C1=O)=O
Structure Classification
Initial Source

new Streptomyces strain
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (90.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8161 mL 9.0803 mL 18.1607 mL
5 mM 0.3632 mL 1.8161 mL 3.6321 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (2.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.27%

COA (249 KB) RP-HPLC (149 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8161 mL 9.0803 mL 18.1607 mL 45.4017 mL
5 mM 0.3632 mL 1.8161 mL 3.6321 mL 9.0803 mL
10 mM 0.1816 mL 0.9080 mL 1.8161 mL 4.5402 mL
15 mM 0.1211 mL 0.6054 mL 1.2107 mL 3.0268 mL
20 mM 0.0908 mL 0.4540 mL 0.9080 mL 2.2701 mL
25 mM 0.0726 mL 0.3632 mL 0.7264 mL 1.8161 mL
30 mM 0.0605 mL 0.3027 mL 0.6054 mL 1.5134 mL
40 mM 0.0454 mL 0.2270 mL 0.4540 mL 1.1350 mL
50 mM 0.0363 mL 0.1816 mL 0.3632 mL 0.9080 mL
60 mM 0.0303 mL 0.1513 mL 0.3027 mL 0.7567 mL
80 mM 0.0227 mL 0.1135 mL 0.2270 mL 0.5675 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Manumycin A Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Manumycin A52665-74-4Farnesyl TransferaseRasApoptosisPhospholipaseTNF ReceptorAtg8/LC3FtaseTumor Necrosis Factor ReceptorTNFRAutophagy-related 8| antibioticbreast cancerlung cancerantiinflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Manumycin A
Cat. No.:
HY-N6796
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.